Post Reply
21-40 of 351
I find it funny that very less ppl are interested in this stock.
I expect Raffles Medical to become $4 within a year.
Huat ah!!!!! 
This stock is sure to go up overtime.
Just need to be patient with it.
Now trading @ 3.24 liao!😊
My next target is $3.40...coming soon...then $3.80
Profit should grow with the expansion in the hospital space.
Raffles Medical Group: 2Q13 results in-line with expectations
Raffles Medical Group (RMG) reported its 2Q13 results this morning which were within our expectations.
Revenue rose 12.9% YoY and 7.1% QoQ to S$86.8m. PATMI was up 15.9% YoY and 6.8% QoQ to S$14.4m. Growth during the quarter was driven by higher patient acuity and an increased depth and breadth of medical services on offer. Both RMG’s core divisions contributed to its topline increase, with its Hospital Services and Healthcare Services segments growing 16.8% and 6.5% YoY, respectively.
For 1H13, revenue increased 12.1% YoY to S$167.9m, forming 48.3% of our full-year estimates while PATMI jumped 16.0% to S$27.9m, or 45.9% of our FY13 forecast. This is unsurprising, as 2H is seasonally a much stronger half for RMG, and we expect this trend to be maintained this year. An interim dividend of 1 S cent/share was declared (payable on 29 Aug 2013), similar to 2Q12 and our forecast.
We will provide more details after the analyst briefing. We maintain our BUY rating and S$3.42 fair value estimate (29x blended FY13/14F). (Wong Teck Ching Andy)
Raffles Medical Group said its second-quarter net profit rose 15.7% from a year earlier to $14.5 million and its revenues rose 12.9% to a record high of $86.8 million.
...last done: $3.17...
Raffles Medical Group - Appreciating “Boring” Growth....
Upgrade to BUY. In recent months, the company has seen expansion plans scuppered, with the unsuccessful tender of a greenfield Hong Kong hospital and failed application to use its Thongsia Building as a medical centre. In the current market environment however, we think there is much to love about a company which has been resilient in delivering earnings growth. Organic hospital expansion and a possible China project will add a dose of excitement.
Raffles Hospital Expansion to drive organic growth. No harm done from these setbacks, as we expect the Group to reap a non-operational gain from the sale of Thong Sia Building. Raffles Hospital expansion is still expected to start by this year. With current bed utilization at around 60%, we believe there is further room to grow hospital revenue at current trajectory (up around 15% yoy in past twelve months.
Still in active discussions for Shekou, Shenzhen hospital. Given the timelines involved upon signing the letter of intent in Feb 2013, we believe a more concrete development could materialize over the next 2 months. We examine the China healthcare industry in more depth and conclude that potential returns from this 200 bed international hospital is comparable to existing matrixes, while the long-term potential is significant for Raffles Medical. Our primary estimate is for this hospital alone to add around SGD18.5m a year in profit (or 30% of current bottomline and SGD3.4 cents EPS) once it turns operational.
More aggressive expansion on the cards. In targeting China, management sees the potential beyond a single hospital, and will likely kick on from there. The company also appears to be adopting a more aggressive stance, after years of conservative organic growth. Based on our estimates, the company can easily fund both the Raffles Hospital expansion and the potential new Shekou project without going into debt.
Much to love about this company. Profitability has grown for 16 years in a row and this resiliency is much prized in the current environment. We upgrade the stock to a BUY, with a new TP of SGD3.80, factoring in higher cash flows (still based on a three-stage DCF methodology). This implies 28.8x FY13F, which is comparable to Asian-listed peers. ...Last Done: $3.09...
Raffles Medical Group posts 16% rise in 1Q earnings to $13.5mil
Raffles Medical Group said earnings grew 16% to $13.5 million for the first quarter ended March 31 (1QFY2013) from $11.6 million in 1QFY2012 due to higher operating profits on improved revenue performance and higher operating efficiencies.
In the same period, revenue rose 11.2% to $81.1 million from $72.9 million. The double-digit growth in revenue was mainly attributable to contributions from the Hospital and Healthcare Services segments, which increased by 16.4% and 4.0% respectively. Higher patient acuity and the addition of specialist consultants have expanded the depth and breadth of medical services provided by the group, which also contributed to the better performance.
As at March 31, the group had a healthy cash position of $102.6 million after repaying a bank loan of $16 million in February 2013. The group continues to enjoy and benefit from its strong operating cashflows from its various business units. This cash position will support the group’s growth and expansion plans in the medium term.
...Prev Close: $3.440...
... Married Deal: Vol: 100 Value: $325,800 ie $3.258 / share Prev Close: $3.26 ...
Big Plans
Lined Up Hold, TP $3.45
FY12 results were within expectations. Recurring net profit grew 10%
yoy, driven by revenue growth of 14% during the period.
The company signed a Letter of Intent with China Merchants Group to
collaborate on the development of an international hospital in Shekou,
Shenzhen. This could mark the Group’s foray into China.
With aggressive growth plans and track record of steady earnings growth,
we upgrade our TP to SGD3.45, but maintain our HOLD valuation, given
the limited upside of 7% from here.
Raffles Medical Group: Maintain HOLD on rich valuations
RafflesMG reported its FY12 results which were within our expectations. Revenue grew 14.2% to S$311.6m, and just 0.1% shy of our forecast. Reported PATMI rose 12.8% to S$56.8m. However, if we exclude the fair value gain in investment properties amounting to S$3.9m, we estimate that core PATMI rose 9.7% to S$52.9m, which is 0.7% higher than our earnings projection. A final dividend of 3.5 S cents/share was declared, bringing full-year DPS to 4.5 S cents (FY12 yield of 1.4%). Looking ahead, we believe that RMG has set its sights on expanding its hospital operations beyond its core market Singapore. We retain our FY13 estimates and introduce our FY14 forecasts. Ascribing a higher PE valuation peg of 27x (previously 24x), we raise our fair value estimate on RMG from S$2.68 to S$3.01. But we maintain HOLD given RMG’s rich valuations. (Wong Teck Ching Andy)
RafflesMG reported its FY12 results which were within our expectations. Revenue grew 14.2% to S$311.6m, and just 0.1% shy of our forecast. Reported PATMI rose 12.8% to S$56.8m. However, if we exclude the fair value gain in investment properties amounting to S$3.9m, we estimate that core PATMI rose 9.7% to S$52.9m, which is 0.7% higher than our earnings projection. A final dividend of 3.5 S cents/share was declared, bringing full-year DPS to 4.5 S cents (FY12 yield of 1.4%). Looking ahead, we believe that RMG has set its sights on expanding its hospital operations beyond its core market Singapore. We retain our FY13 estimates and introduce our FY14 forecasts. Ascribing a higher PE valuation peg of 27x (previously 24x), we raise our fair value estimate on RMG from S$2.68 to S$3.01. But we maintain HOLD given RMG’s rich valuations. (Wong Teck Ching Andy)
do these [url=http://finance.yahoo.com/education/stocks#Investment%20Approaches%20and%20Strategies]basics[/url] about stocks help one?
Starts to move quietly... 
moves up quitely. Now 2.46.
Why did the price move so drmatically in the last minute?
| Time | Type | Last Done | Chg | Volume ('000) | |
|---|---|---|---|---|---|
| Change | Total | ||||
| 17:04:46 | Preclose | 2.410 | - | 14 | 474 |
| 16:59:42 | Sell Down | 2.410 | - | 1 | 460 |
| 16:55:00 | Buy Up | 2.440 | +0.030 | 1 | 459 |
| 16:54:21 | Sell Down | 2.430 | +0.020 | 1 | 458 |
| 16:52:01 | Sell Down | 2.430 | +0.020 | 1 | 457 |
| 16:49:40 | Sell Down | 2.430 | +0.020 | 1 | 456 |
| 16:47:20 | Sell Down | 2.430 | +0.020 | 1 | 455 |
| 16:44:59 | Sell Down | 2.430 | +0.020 | 1 | 454 |
| 16:42:11 | Buy Up | 2.440 | +0.030 | 1 | 453 |
| 16:39:04 | Buy Up | 2.440 | +0.030 | 1 | 452 |
| 16:38:58 | Buy Up | 2.440 | +0.030 | 2 | 451 |
| 16:35:58 | Sell Down | 2.420 | +0.010 | 1 | 449 |
| 16:31:17 | Sell Down | 2.420 | +0.010 | 1 | 448 |
for mid caps, raffles medical is one of the most defensive play